Log In
Print
BCIQ
Print
Print this Print this
 

Fenoglide (formerly LCP-FenoChol)

  Manage Alerts
Collapse Summary General Information
Company Veloxis Pharmaceuticals A/S
DescriptionSolid solution MeltDose formulation of low-dose fenofibrate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDyslipidemia
Indication DetailsTreat dyslipidemia
Regulatory Designation
Partner Shore Therapeutics Inc.; Valeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$15,640.0M

$14,800.0M

$5.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today